BIRMINGHAM, Ala. — January 8, 2025 — Rampart, a Birmingham, Alabama–based
medical device company redefining interventional radiation safety, today announced the
launch of the SECURE Clinical Program, Studies Evaluating Clinical Utility of Radiation
mitigation Equipment, a first-of-its-kind, multi-specialty clinical initiative designed to
further advance the scientific evidence for next-generation radiation protection.
The SECURE Clinical Program is a coordinated series of clinical studies spanning multiple
interventional specialties—including interventional cardiology, electrophysiology,
endovascular, aortic, and neurovascular—all evaluating the use of Rampart’s suite of
Enhanced Radiation Protection Devices (ERPD). By expanding clinical investigation across
diverse procedures and care environments, SECURE is intended to deepen and broaden
the understanding of how modern radiation protection can improve safety for clinicians
and care teams without compromising procedural performance.
“SECURE represents a major milestone not only for Rampart, but for the entire field of
interventional medicine,” said Dr. Bob Foster, Founder and Chief Medical Officer at
Rampart. “Radiation exposure remains an unavoidable reality in interventional care. With
the SECURE Clinical Program, we are setting a new standard for how radiation protection
technologies are clinically evaluated—across specialties, across procedures, and
grounded in rigorous evidence.”
The launch of SECURE builds on Rampart’s existing body of clinical evidence, which
already includes two randomized controlled trials demonstrating superiority over standard
lead aprons and traditional shields—a distinction unique to Rampart in the radiation
protection market. The program is designed to add further depth and real-world relevance
Commented [BC1]: Studies Evaluating Clinical Utility of
Radiation mitigation Equipment to this evidence base by evaluating Rampart’s suite of solutions in varied clinical contexts where scatter radiation exposure is a daily occupational risk.
“Our system was engineered to move beyond incremental improvements and
fundamentally change how radiation protection is delivered,” said Brian Chambless, Chief
Commercial OWicer at Rampart. “SECURE allows us to systematically study that impact
across a wide array of interventional specialties—while continuing to prioritize clinician
safety, comfort, and procedural workflow.”
As a first-of-its-kind initiative in radiation protection, the SECURE Clinical Program
underscores Rampart’s commitment to evidence-driven innovation and its belief that
meaningful improvements in clinician safety must be validated through high-quality clinical
research. As the market leader in barrier-based radiation protection, Rampart also
recognizes a responsibility to lead not only in technology, but in the generation of rigorous
clinical data that informs best practices across interventional care.
ABOUT RAMPART
Rampart is a Birmingham, Alabama–based medical device company redefining
interventional radiation safety through rigorous clinical evidence. Supported by two
randomized controlled trials and more than 1,700 real-world procedures, Rampart’s
solutions deliver 99% scatter radiation reduction and are proven to be up to 20x more
eWective than lead aprons and traditional shields.
Designed with zero pounds of wearable burden and engineered so that it adds no weight to
the clinician or the procedure table, Rampart eliminates the orthopedic strain long
associated with wearing lead aprons while preserving full procedural freedom. All Rampart
radiation protection solutions are manufactured using lead-free materials, supporting a
more sustainable approach to radiation safety while delivering effective scatter-blocking
protection without traditional lead-based shielding. Available nationwide and through
global distribution partnerships, Rampart provides total body, total team protection for
those who work in the interventional suite —empowering providers to confidently Shed the
Lead®.
